u/LUCA_BioSpikes

A prospective study followed 5,301 adults aged 55 and older to examine the relationship between low-carbohydrate and low-fat diets and dementia risk.

The researchers also looked at genetic susceptibility, including APOE genotype and Alzheimer’s disease polygenic risk score.

It looks beyond the diet itself and asks whether the same dietary pattern may be associated with dementia risk differently depending on a person’s genetic background.

Diet and healthy aging are probably not as straightforward as “low-carb vs. low-fat.”

Low-carbohydrate and low-fat diets, genetic susceptibility, and long-term risk of dementia: A prospective cohort study - The American Journal of Clinical Nutrition

I came across this recent consensus paper in Nature Reviews Gastroenterology & Hepatology, and one point really stood out to me.

We have been studying the gut microbiome for years, but there is still a basic problem: different studies don't always collect the same information or measure things in the same way.

For example, diet, medication, probiotic use and other factors can affect the microbiome. Even the way a stool sample is collected, stored and processed can change the results. The paper points out that these differences make studies harder to reproduce and compare.

So the researchers tried to establish some common ground.

They brought together microbiome researchers and clinicians through a two-round Delphi process and reached 15 recommendations covering what information should be recorded, how samples should be handled, and what should be measured in clinical studies. 72 experts took part in the first round and 61 in the second.

I think this is particularly relevant to probiotics and microbiome supplements.

We often see products described as “clinically studied,” followed by things like a change in bacterial abundance or microbiome diversity.

But those numbers don't mean much without knowing who was studied, what else they were doing, how the samples were handled, and what actually happened to their health.

The consensus therefore recommends looking at microbiome measurements together with disease outcomes, safety, biological markers and patient-reported outcomes.

To me, this is an important step for the supplement industry.

A change in the microbiome is interesting. It becomes much more useful when we can reliably connect it to a health outcome.

If more studies start following common standards, “clinically studied” may eventually mean something much more useful than it does today.

https://doi.org/10.1038/s41575-026-01229-1